Greenbrook TMS Inc
TSX:GTMS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (0.3), the stock would be worth CA$0.97 (0% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.3 | CA$0.97 |
0%
|
| 3-Year Average | 0.3 | CA$0.97 |
+0%
|
| 5-Year Average | 0.3 | CA$0.99 |
+2%
|
| Industry Average | 1.9 | CA$6.06 |
+524%
|
| Country Average | 2.9 | CA$9.36 |
+865%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
CA$28.6m
|
/ |
Jan 2023
$69.1m
|
= |
|
|
CA$28.6m
|
/ |
Dec 2023
$124.5m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Greenbrook TMS Inc
TSX:GTMS
|
28.6m CAD | 0.3 | -0.3 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
106.6B USD | 0.3 | 59.9 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
71B EUR | 0.3 | 14.1 | |
| US |
|
Cigna Corp
NYSE:CI
|
77B USD | 0.3 | 12.9 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.3B EUR | 1 | 18.4 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.5B EUR | 1.1 | 22.8 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.1B USD | 1.5 | 24.3 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21B USD | 1.9 | 21.1 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.6B EUR | 0.5 | 10.8 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
10.9B USD | 11.4 | -26.8 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 0.8 | 14.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.4 |
| Median | 2.9 |
| 70th Percentile | 4.9 |
| Max | 15 623 917.6 |
Other Multiples
Greenbrook TMS Inc
Glance View
Greenbrook Tms, Inc. engages in the provision of transcranial magnetic stimulation, an FDA-cleared, non-invasive therapy for the treatment of major depressive disorder. The company is headquartered in Toronto, Ontario and currently employs 430 full-time employees. The company went IPO on 2018-10-03. The TMS therapy is a non-invasive therapy for the treatment of depressive disorder (MDD) and other mental health disorders. The TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. The firm's patient-focused, customer service model provides TMS therapy accessible to all patients through three business processes: Patient Inquiry; Patient Conversion; and Treatment Delivery. A course of TMS consists of 36 treatments and a course of treatment consist of an initial cortical mapping and motor threshold determination and treatment, daily treatment sessions and a subsequent motor threshold re-determination and treatment. The company operates through approximately 130 Company-operated treatment centers. The company operates across the States of North Carolina, South Carolina, Maryland, Delaware, Missouri, Illinois, and Ohio.
